Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

2525 with DOI

11 strong · 14 moderate · 0 weak

Compilations

12026-05-11T12:45:42.945Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

49last ruled 2026-10-02

0 awaiting a ruling

Issued documents

62026-10-19T20:34:09.384Z

notice · info card · emergency

Searches

161 with no results

queries and counts on the build

Claims checked

6045 supported

45 supported · 15 not

Correspondence

0received

consent field ships in Phase 4

Edges

231

derivations recorded for this entity

Complete over 25 sources, 1 compilation, and 49 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/tetrahydrocannabiphorol/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued emergency
  2. 2026-10-19issueIssued info_card
  3. 2026-10-02issueIssued info_card
  4. 2026-10-02srcAssociation of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence
  5. 2026-10-02srcHuman metabolism of the semi-synthetic cannabinoids hexahydrocannabinol, hexahydrocannabiphorol and their acetates using hepatocytes and urine samples
  6. 2026-10-02srcIn vitro activation of the CB1 receptor by the semi-synthetic cannabinoids hexahydrocannabinol (HHC), hexahydrocannabinol acetate (HHC-O) and hexahydrocannabiphorol (HHC-P)
  7. 2026-10-02srcIdentification of Hexahydrocannabiphorol Metabolites in Human Urine
  8. 2026-10-02srcInvestigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays - and how this matters for the harm potential of seized drugs
  9. 2026-10-02srcEnantioseparation of chiral phytocannabinoids in medicinal cannabis
  10. 2026-10-02srcSingle trichome phytocannabinomics of two different cannabis varieties
  11. 2026-10-02srcPhytocannabinoids: Origins and Biosynthesis
  12. 2026-10-02srcRates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis
  13. 2026-10-02srcA novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol
  14. 2026-10-02srcIdentification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol
  15. 2026-10-02srcAppearance of hexahydrocannabinols as recreational drugs and implications for cannabis drug testing - focus on HHC, HHC-P, HHC-O and HHC-H
  16. 2026-10-02srcCross-reactivity of 24 cannabinoids and metabolites in blood using the Immunalysis Cannabinoids Direct enzyme-linked immunosorbent assay
  17. 2026-10-02srcComprehensive LC-MS-MS analysis of THC isomers, analogs, homologs, and metabolites in blood and urine
  18. 2026-10-02srcRapid LC-QTOF-MS screening method for semi-synthetic cannabinoids in whole blood
  19. 2026-10-02srcThe Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications
  20. 2026-10-02srcEmergence of semi-synthetic cannabinoids in cannabis products seized in Eastern Denmark over a 6-year period
  21. 2026-10-02srcCannabidiol-Derived Cannabinoids: The Unregulated Designer Drug Market Following the 2018 Farm Bill
  22. 2026-10-02srcEvidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology
  23. 2026-10-02srcAn emerging trend in Novel Psychoactive Substances (NPSs): designer THC
  24. 2026-10-02srcMarijuana Use and Its Impact on Outpatient Anesthesia.
  25. 2026-10-02srcExogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
  26. 2026-10-02srcBeyond THC: The New Generation of Cannabinoid Designer Drugs
  27. 2026-10-02srcCBD Versus CBDP: Comparing In Vitro Receptor-Binding Activities
  28. 2026-10-02srcThe Identification of Synthetic Impurities in a Vape Pen Containing Δ9-Tetrahydrocannabiphorol Using Gas Chromatography Coupled with Mass Spectrometry
  29. 2026-10-02publicationPublication — publishagent-psx
  30. 2026-10-02revisionr1.a1
  31. 2026-10-02rulingRuling — psx:substance/tetrahydrocannabiphorol/proposal/article_section_proposals/cb58f7bd-d470-4698-a4be-c568c82b9cd9founder
  32. 2026-10-02rulingRuling — psx:substance/tetrahydrocannabiphorol/proposal/article_section_proposals/d2c334dd-2c8f-452b-a4d2-c3129be5d86efounder
  33. 2026-09-04issueIssued emergency
  34. 2026-09-04issueIssued info_card
  35. 2026-09-04issueIssued notice
  36. 2026-06-04proposal43 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  37. 2026-06-04publicationPublication — backfill
  38. 2026-05-11revisionRevision 1
  39. 2026-05-11absenceSearched ClinicalTrials.gov for "tetrahydrocannabiphorol THCP" — no results
  40. 2026-05-11genGeneration — pipeline-v5 · with 3 morepipeline-v5
  41. 2026-05-11rungeneration run

The same entries, as forms: six forms.